Doctors and patients don't agree: Cross sectional study of patients' and doctors' perceptions and assessments of disability in multiple sclerosis

British Medical Journal

Volumn 314, Issue 7094, 1997, Pages 1580-1583

  Rothwell, P M ^a,b   McDowell, Z ^a   Wong, C K ^a   Dorman, P J ^a  

^a WESTERN GENERAL HOSPITAL   (United Kingdom)

^b RADCLIFFE INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DOCTOR PATIENT RELATION; FEMALE; HEALTH STATUS; HUMAN; MALE; MENTAL HEALTH; MULTIPLE SCLEROSIS; OUTCOMES RESEARCH; PERCEPTION; PHYSICAL DISABILITY; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; SELF EVALUATION;

EID: 0030967027     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: 10.1136/bmj.314.7094.1580     Document Type: Article

References (22)

1. Noseworthy JH, Ebers GC. Vandervoort MK. Farquhar RE, Yetisir E, Roberts R. The impact of blinding on the results of a randomized, placebo-controlled multiple sclerosis clinical trial. Neurology 1994;11:16-20.
2. IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993;43: 655-61.
3. IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993;43:662-7.
4. IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group. Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology 1995;45:1277-85.
5. Jacobs LD, Cookfair DL, Rudick AR, Herndon RM, Richert JR, Salazar AM, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 1996;39:285-94.
6. Brazier JE, Harper R, Jones NMB, O'Cathain A, Thomas KJ, Usherwood T, et al. Validating the SF-36 health survey questionnaire: new outcome measure for primary care. BMJ 1992;305:160-4.
7. Garratt AM, Ruta DA, Abdalla MI, Buckingham JK, Russell IT. The SF-36 health survey questionnaire: an outcome measure suitable for routine use within the NHS? BMJ 1993;306:1440-4.
8. Poser CM, Paty DW, Scheinberg DH, McDonald WI, Davis FA, Ebers GC, et al. New diagnostic criteria for multiple sclerosis. Ann Neurol 1983;13:227-31.
9. Kurtzke JE. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983;33:1444-52.
10. Amato MP, Fratiglioni L, Groppi C, Siracusa G, Amaducci L. Interrater reliability in assessing functional systems and disability on the Kurtzke scale in multiple sclerosis. Arch Neurol 1988;45:746-8.
11. Martin J, Meltzer H, Elliot D. OPCS surveys of disability in Great Britain. I The prevalence of disability among adults. London: OPCS, 1988.
12. EuroQol Group. EuroQol: a new facility for measurement of health related quality of life. Health Policy 1990;16:199-208.
13. Cohen G, Forbes J, Garraway M. Interpreting self reported limiting long term illness. BMJ 1995;311:722-1.
14. Slevin ML, Plant H, Lynch D, Drinkwater J, Gregory WM. Who should measure the quality of life, the doctor or the patient? Br J Cancer 1988;57:109-12.
15. Gerhart KA, Koziol-McLain J, Lowenstein SR, Whiteneck GG. Quality of life following spinal cord injury: knowledge and attitudes of emergency care providers. Ann Emerg Med 1994;23:807-12.
16. O'Boyle CA, McGee H, Hickey A, O'Malley K, Joyce CRB. Individual quality of life in patients undergoing hip replacement. Lancet 1992;339:1088-91.
17. Goodare H, Smith R. The rights of patients in research: patients must come first in research. BMJ 1995;310:1277-8.
18. Chalmers I. What do I want from health research and researchers when I am a patient? BMJ 1995;310:1315-8.
19. Hutchinson J, Hutchinson M. The function limitations profile may be a valid, reliable and sensitive measure of disability in multiple sclerosis. J Neurol 1995;242:650-7.
20. Vickrey BG, Hays RD, Harooni R, Myers LW, Ellison GW A health-related quality of life measure for multiple sclerosis. Qual Life Res 1995;4:187-206.
21. Schwartz CE, Cole BF, Gelber RD. Measuring patient-centred outcomes in neurologic disease. Arch Neurol 1995;52:754-62.
22. Neilley LK, Goodwin DS, Goodkin DE, Hauser SL. Side effect profile of Interferon beta-1b in MS: results of an open label trial. Neurology 1996;46:552-4.